MA43879B1 - Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones - Google Patents

Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Info

Publication number
MA43879B1
MA43879B1 MA43879A MA43879A MA43879B1 MA 43879 B1 MA43879 B1 MA 43879B1 MA 43879 A MA43879 A MA 43879A MA 43879 A MA43879 A MA 43879A MA 43879 B1 MA43879 B1 MA 43879B1
Authority
MA
Morocco
Prior art keywords
imipridones
modulation
protein
conditions
gpcr
Prior art date
Application number
MA43879A
Other languages
English (en)
Other versions
MA43879A (fr
Inventor
Martin Stogniew
Joshua E. Allen
Varun Vijay PRABHU
Original Assignee
Oncoceutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/fr
Application filed by Oncoceutics, Inc. filed Critical Oncoceutics, Inc.
Publication of MA43879A publication Critical patent/MA43879A/fr
Publication of MA43879B1 publication Critical patent/MA43879B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)

Abstract

Les imipridones se sont avérées moduler sélectivement les récepteurs couplés aux protéines G (RCPG) de classe A, comme la sous-famille de type D2 de récepteurs dopaminergiques et être utiles pour le traitement de pathologies et de troubles nécessitant une telle modulation, comme les cancers, les troubles psychiatriques et les infections bactériennes. De plus, l'invention concerne des procédés permettant d'identifier si un sujet présentant ces pathologies est susceptible de répondre à un schéma thérapeutique tel que l'administration d'une imipridone. En outre, l'invention concerne des procédés permettant d'évaluer l'efficacité d'un schéma thérapeutique tel que l'administration d'une imipridone, de surveiller ou de fournir un pronostic pour un sujet atteint de ces pathologies.
MA43879A 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones MA43879B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (fr) 2015-01-30 2016-01-29 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogues et sels de ce composé et leur utilisation en thérapie
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22
PCT/US2017/015608 WO2017132661A2 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones
EP17745078.0A EP3408298B1 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Publications (2)

Publication Number Publication Date
MA43879A MA43879A (fr) 2018-12-05
MA43879B1 true MA43879B1 (fr) 2025-02-28

Family

ID=59398848

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43879A MA43879B1 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Country Status (25)

Country Link
US (2) US11116771B2 (fr)
EP (2) EP4524567A3 (fr)
JP (2) JP7030701B2 (fr)
KR (2) KR102801670B1 (fr)
CN (2) CN115844895B (fr)
AU (2) AU2017211423B2 (fr)
BR (1) BR112018015590A2 (fr)
CA (1) CA3013044A1 (fr)
DK (1) DK3408298T3 (fr)
ES (1) ES3012491T3 (fr)
FI (1) FI3408298T3 (fr)
HR (1) HRP20250207T1 (fr)
HU (1) HUE070208T2 (fr)
IL (3) IL286923B2 (fr)
LT (1) LT3408298T (fr)
MA (1) MA43879B1 (fr)
MX (2) MX2018009227A (fr)
NZ (1) NZ745425A (fr)
PL (1) PL3408298T3 (fr)
PT (1) PT3408298T (fr)
RS (1) RS66519B1 (fr)
SG (2) SG11201806401YA (fr)
SI (1) SI3408298T1 (fr)
SM (1) SMT202500086T1 (fr)
WO (1) WO2017132661A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20210125683A1 (en) * 2017-09-15 2021-04-29 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
US11674963B2 (en) 2017-09-27 2023-06-13 The Regents Of The University Of California GPCRs in cancer-associated fibroblasts
CA3089864A1 (fr) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methodes de traitement de pathologies fibrotiques
JP2021521141A (ja) * 2018-04-09 2021-08-26 オージェネシス インコーポレイテッド バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物
CN109157656B (zh) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 一种双靶标肿瘤疫苗及其制备方法和应用
US20220143024A1 (en) * 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
EP4378532B1 (fr) 2019-07-30 2025-11-12 Mayo Foundation for Medical Education and Research Composés et procédés pour traiter des pathologies fibrotiques
KR102403686B1 (ko) 2020-05-15 2022-05-31 뉴로핏 주식회사 뇌자극 위치 제공장치 및 방법
EP4192467A1 (fr) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthèse de nouveaux dérivés d'imipridone et leur évaluation concernant leur activité anticancéreuse
CN112402439A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
WO2024031030A2 (fr) * 2022-08-03 2024-02-08 Shi Xiandong Procédé quantitatif pour déterminer un état mental fondé sur drd1 et/ou drd5, et son application
CN115531378B (zh) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Pht427作为ndm-1与kpc-2双重抑制剂的应用
WO2024157207A1 (fr) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Inhibiteurs de gpcr et leurs utilisations
WO2024218275A1 (fr) * 2023-04-20 2024-10-24 Institut Gustave Roussy Compositions liquides et solides de dérivés de l'imipridone
CN116731136B (zh) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (fr) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
US20070026402A1 (en) * 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
CA2699912A1 (fr) 2007-09-19 2009-03-26 Oncofluor, Inc. Procede d'imagerie et de traitement d'organes et de tissus
CA2865819A1 (fr) 2011-02-28 2013-09-07 Mcmaster University Traitement du cancer par des antagonistes des recepteurs dopaminergiques
PT2701708T (pt) * 2011-04-29 2020-05-08 Penn State Res Found Indução de gene trail de moléculas pequenas através de células tumorais e normais como uma terapia anticancro
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (fr) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
RS59013B1 (sr) 2013-03-13 2019-08-30 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera
HUE043291T2 (hu) * 2013-11-15 2019-08-28 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(lH)-on, sói és alkalmazási eljárások
US10239877B2 (en) * 2014-03-31 2019-03-26 The Scripps Research Institute Pharmacophore for trail induction
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
BR112018015590A2 (pt) * 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
IL286923B1 (en) 2024-12-01
HRP20250207T1 (hr) 2025-04-11
AU2022200583A1 (en) 2022-02-24
EP3408298A2 (fr) 2018-12-05
SG10202108306UA (en) 2021-08-30
ES3012491T3 (en) 2025-04-09
NZ745425A (en) 2023-03-31
AU2017211423B2 (en) 2021-10-28
WO2017132661A2 (fr) 2017-08-03
SI3408298T1 (sl) 2025-05-30
US20220072001A1 (en) 2022-03-10
US11116771B2 (en) 2021-09-14
NZ784773A (en) 2025-05-02
KR20180125460A (ko) 2018-11-23
LT3408298T (lt) 2025-03-10
RS66519B1 (sr) 2025-03-31
IL286923B2 (en) 2025-04-01
JP2019511460A (ja) 2019-04-25
DK3408298T3 (en) 2025-03-03
AU2022200583B2 (en) 2024-05-02
MA43879A (fr) 2018-12-05
EP4524567A2 (fr) 2025-03-19
WO2017132661A3 (fr) 2017-08-31
AU2017211423A1 (en) 2018-09-06
IL286923A (en) 2021-10-31
CA3013044A1 (fr) 2017-08-03
PL3408298T3 (pl) 2025-03-31
KR20250065717A (ko) 2025-05-13
JP7030701B2 (ja) 2022-03-07
JP2022046528A (ja) 2022-03-23
MX2023004443A (es) 2023-05-08
EP3408298A4 (fr) 2019-09-04
IL260815B (en) 2021-10-31
CN109311980B (zh) 2023-01-17
BR112018015590A2 (pt) 2019-10-01
HUE070208T2 (hu) 2025-05-28
KR102801670B1 (ko) 2025-04-25
US20190307751A1 (en) 2019-10-10
CN115844895B (zh) 2025-10-17
CN115844895A (zh) 2023-03-28
FI3408298T3 (fi) 2025-02-24
SG11201806401YA (en) 2018-08-30
IL316540A (en) 2024-12-01
MX2018009227A (es) 2018-11-09
EP4524567A3 (fr) 2025-07-23
SMT202500086T1 (it) 2025-03-12
CN109311980A (zh) 2019-02-05
PT3408298T (pt) 2025-03-20
EP3408298B1 (fr) 2024-11-20

Similar Documents

Publication Publication Date Title
MA43879B1 (fr) Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
EP4023920A4 (fr) Appareil d'ajustement pour le raccordement de tuyaux
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
CR20200201A (es) Ensamble de riel con adaptador de montaje lateral invertible para aplicaciones de montaje directo e indirecto
MA49459A (fr) Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
EP3607715A4 (fr) Détection de redémarrage d'un consommateur de services de nf à l'aide d'une signalisation directe entre nf
FR3030516B1 (fr) Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
MA43468A1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA46148A1 (fr) Systèmes et procédés de capture d'image dans une capsule de culture de ligne d'assemblage
WO2018220060A3 (fr) Raccords d'instrument et procédés associés
EP1986118A3 (fr) Système et procédé pour la gestion de certificats numériques sur un dispositif distant
EP3829372A4 (fr) Système de vêtement assurant une surveillance biométrique pour l'évaluation d'un état médical
PL4125881T3 (pl) Nowe zastosowanie agonisty receptora angiotensyny ii typu 2
MA39164A1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
EP3766207A4 (fr) Dispositifs et procédés pour la détermination de la qualité de service des applications basées sur l'iot
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
BR112017025796A2 (pt) dispositivo de acoplamento rápido
AR058959A1 (es) Metodos para modular receptores de la superficie celular para prevenir o reducir la inmflamacion
FR3019654B1 (fr) Controles pour la mise en oeuvre de procedes d'analyse multiplexe
MA30763B1 (fr) Forme cristalline polymorphe d'un derive de maleate d'indan-2-ylamino-hydroxyethyl-quinolinone en tant qu'agoniste du recepteur beta-adrenergique
FR3048883B1 (fr) Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
MA54518B1 (fr) 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs
FR3063654B1 (fr) Ensemble video pour table de babyfoot et table de babyfoot l'incorporant